Argireline
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Argireline is listed as beauty / topical neuro-cosmetic.
- •Expression lines
- •Forehead/crow's-feet wrinkles
Regulatory status: Cosmetic ingredient (global).
Structure & Properties
Compound: Argireline; also known as Acetyl Hexapeptide-3, Acetyl Hexapeptide-8.
Pharmacologic class: Beauty / Topical Neuro-Cosmetic.
Known delivery routes: Topical.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Mimics SNAP-25 N-terminus — competitively inhibits SNARE complex formation, reducing catecholamine release and micro-contractions in mimic muscles.
- •Reduces expression-line depth
- •Non-invasive 'topical botox' alternative
- •Well tolerated
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Cosmetic RCTs vs placebo.
Laboratory Research
Cosmetic RCTs vs placebo
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Topical AM and PM to expression-line areas.
Potential interactions and combinations to avoid
- •No systemic interactions
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Mild irritation
- •Modest effect vs injectables
Contraindications
- •Application on broken skin
- •Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- •Bipolar disorder, psychosis, or active mania
- •Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- •Recent intracranial haemorrhage or unstable neurologic injury
- •Broken, infected, sunburned, or actively inflamed skin
- •Concurrent prescription retinoid, chemical peel, or laser resurfacing without dermatologic guidance
- •Known copper sensitivity or Wilson's disease (copper-carrier peptides)
- •Eczema, rosacea, or perioral dermatitis in active flare
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 5–10% in topical formulation
Frequency: 1–2× daily
Cycling: Continuous topical use.
Topical
Expression-line areas (forehead, crow's feet).
Serum or cream (5–10%). Apply AM and PM to expression lines. Full effect ~4 weeks.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Matrixyl, GHK-Cu (offset applications)
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Argireline?
In plain words
Argireline is a small protein-like ingredient used in skin cosmetics. It interferes with proteins involved in releasing nerve signals, reducing tiny contractions in facial expression muscles. Researchers study it for expression lines, including forehead wrinkles and crow’s-feet. Clinical evidence is limited, effects are modest compared with injections, and mild skin irritation can occur.
Technical definition
Argireline, also known as Acetyl Hexapeptide-3 or Acetyl Hexapeptide-8, is an acetylated six-amino-acid peptide used in topical neuro-cosmetics that mimics the N-terminal region of SNAP-25. It competitively inhibits formation of the SNARE protein complex, reducing catecholamine release and small contractions in facial expression muscles. It is a cosmetic ingredient globally, not an FDA-approved drug; randomized controlled clinical evidence is limited.
Function
Dosing
Recommended Time of Day
Topical, morning and evening skincare routine.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Face / neck (topical) — Clean dry skin, AM and PM, before moisturizer.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous topical use.
Timing & Interactions
- ·No systemic interactions
- ·Matrixyl, GHK-Cu (offset applications)
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Argireline and sync them to Vial Lab.
Benefits
- ·Reduces expression-line depth
- ·Non-invasive 'topical botox' alternative
- ·Well tolerated
Risks
- ·Mild irritation
- ·Modest effect vs injectables
Contraindications
- ·Application on broken skin
- ·Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- ·Bipolar disorder, psychosis, or active mania
- ·Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- ·Recent intracranial haemorrhage or unstable neurologic injury
- ·Broken, infected, sunburned, or actively inflamed skin
- ·Concurrent prescription retinoid, chemical peel, or laser resurfacing without dermatologic guidance
- ·Known copper sensitivity or Wilson's disease (copper-carrier peptides)
- ·Eczema, rosacea, or perioral dermatitis in active flare
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Cosmetic ingredient (global)
Veterinary Use (Pets)
No established veterinary protocol for Argireline. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →